University of Maryland Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial
In this study, patients with confirmed positive COVID-19 tests receive imatinib for a total of 14 days; 400 mg orally daily Days 1-14. Imatinib 400 mg tablets will be encapsulated using size 000 capsules and cellulose microcrystalline filler. For patients on ventilator or ECMO, imatinib will be given as oral suspension (40 mg/mL). To make the oral suspension, imatinib tablets will be crushed and mixed in Ora-sweet solution to yield a concentration of 40 mg/mL suspension by pharmacy. Additionally, in the absence of supportive microbiological testing results, we confirm that the in-use stability period for the prepared imati...
Source: Trials - October 28, 2020 Category: Research Source Type: clinical trials

Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants
Condition: HIV Infections Interventions: Biological: GEO-D02 DNA; Biological: MVA/HIV62B Vaccine; Biological: B63521^11 gp120; Biological: IHV01 Protein; Biological: Protein Placebo Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine Trials Network (HVTN), Fred Hutch / University of Washington; GeoVax Labs, Inc; Duke University; Institute of Human Virology, School of Medicine, University of Maryland Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials